CervoMed Inc. (CRVO)
CRVO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1053691/000143774926008259/0001437749-26-008259-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CRVO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001053691 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.0M |
| Net income | -$27.0M |
| Operating income | -$28.3M |
| Net margin | -673.1% |
| Operating margin | -706.2% |
| Revenue growth | -58.9% |
| Cash | $8.2M |
| Total assets | $22.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 6.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Accordingly, substantial doubt about the Company's ability to continue as a going concern is not alleviated." | 10-Q 2026-11-06 |
| Cash and burn | $6.1M cash; operating cash flow -$6.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 15,128,540 (2026-11-04); 9,252,719 a year earlier; 5,674,520 three years earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-06-22 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | RSM US LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $3.5M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$5.9M | -$5.1M | $6.1M | No debt tags | $9K | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | $0 | -$6.6M | -$6.9M | $22.5M | No debt tags | $331K | 10-Q 2026-08-07 |
| Q1 2026 2026-03-31 | $0 | -$8.0M | -$8.0M | $7.9M | No debt tags | $2.1M | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $9K | -$8.1M | -$6.6M | $8.2M | No debt tags | $4.0M | 10-K 2026-03-13 |
| Q3 2025 2025-09-30 | $323K | -$7.7M | -$6.5M | $9.4M | No debt tags | $6.2M | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | $1.8M | -$6.3M | -$6.5M | $8.3M | No debt tags | $7.8M | 10-Q 2026-08-07 |
| Q1 2025 2025-03-31 | $1.9M | -$4.9M | -$3.9M | $10.5M | No debt tags | $9.3M | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $2.2M | -$6.7M | -$8.1M | $9.0M | No debt tags | $9.7M | 10-K 2026-03-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B3 | 424B3 | 2026-07-10 |
| Latest annual report FORM 10-K | 10-K | 2026-03-13 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-06 |
| Latest current report FORM 8-K | 8-K | 2026-11-16 |
| Latest proxy FORM DEF 14A | DEF 14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +19.0% |
| 1 month | -25.6% |
| 3 months | -42.3% |
| Year to date | -78.6% |
| 1 year | -76.7% |
| From 52-week high | -83.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ABVC | ABVC BioPharma Inc. | $0.9400 | +3.30% | $25.4M |
| IMMP | Immutep Limited | $3.40 | -2.30% | $25.1M |
| EDSA | Edesa Biotech Inc. Common Shares | $1.89 | -2.58% | $25.5M |
| LITS | Lite Strategy Inc. | $0.8565 | +1.16% | $25.6M |
| ACET | Adicet Bio Inc. | $2.75 | -1.08% | $25.7M |
| IXHL | Incannex Healthcare Inc. | $1.93 | -2.03% | $24.2M |
| MIRA | MIRA Pharmaceuticals Inc. | $0.6310 | -4.38% | $26.5M |
| BYSI | BeyondSpring Inc. | $0.5788 | -3.73% | $23.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier